Ursula Linne-Mclaren briefly discusses valuable guidance for patients and caregivers, particularly those considering bispecific therapies, providing a supportive perspective on the journey through R/R MM treatment.
Ursula Linne-Mclaren, RN
Advertisement
Articles by Ursula Linne-Mclaren, RN
Nurse Linne-Mclaren provides her insights into the proactive measures, monitoring strategies, and experiences related to talquetamab-associated adverse events, along with a broader perspective on prophylactic measures for managing potential adverse events in bispecific therapies.
Ursula Linne-Mclaren, RN, reviews a clinical scenario in a relapsed/ refractory multiple myeloma patient.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
2
Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy
3
3 Things You Should Know About Single-Agent ADCs in TNBC Treatment
4
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
5
